CClinicalTrials.gg
WithdrawnNCT03257332EDFI-CohortUpdated Dec 4, 2020

Determining Early Development of Faecal Incontinence and Anorectal Muscle Function After Surgery for Rectal Cancer.

An observational study in Rectum Cancer, Quality of Life and Faecal Incontinence, sponsored by Slagelse Hospital. Withdrawn at 2 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-04.

Sponsored by Slagelse Hospital · Observational

Why this study was withdrawn
Not possible to include participants
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
0
Ages
18 Years and older
Sex
All
01

Study summary

Background:

Patients treated for rectal cancer are in high risk of developing poor quality of life and faecal incontinence. Faecal incontinence has a negative impact on quality of life. However, there is limited knowledge on how to prevent it. Known exposures are ; age at surgery, gender, tumor height, pre-operative radiotherapy, surgical technique and temporary stoma. In order to evaluate the underlying mechanisms of faecal incontinence, it is central to evaluate the anorectal muscle function for sensory and motor impairment. Exposures representing different constructs in the biopsychosocial model are likewise likely to be associated with quality of life and faecal incontinence. These exposures include sexual dysfunction, urinary incontinence, fatique, physical inactivity and finding meaning in life. There are to our knowledge, no records on these relationships from prior to surgery to 2 years after. These biopsychosocial exposures are central to include when developing strategies that can prevent poor quality of life and faecal incontinence for patients treated for rectal cancer.

Purpose:

The primary purpose of the EDFI-Cohort study is to determine how several variables (surgical technique, anorectal muscle function, faecal incontinence, urinary incontinence, sexual dysfunction, fatigue, physical activity and finding meaning in life) develop over time and predicts quality of life. Secondary how it predicts LARS-score in patients with rectal cancer from prior to surgery to 2 years after primary treatment.

Methods:

We will include subjects diagnosed with rectal cancer and have received curative surgery (low anterior resection) with/without adjuvant (radiation/chemo) therapy. The cohort aim to recruit all eligible patients in a one year period. We estimate to recruit 70 patients.

Self-reported outcomes will be collected with a series of validated questionnaires that subjects will be asked to complete 6 times during the two year study at 3, 6, 12, 26 78 and 104 weeks. Outcomes include: Quality of life using (EORTC QLQ-C30) (primary outcome), (CR29) and (FA12), bowel related quality of life (LARS-score) (secondary outcome), faecal incontinence (Vaizey score), urinary incontinence (ICIQ-UI), (MLUTS/FLUTS) and (MLUTSsex/FLUTSsex), physical activity level from Danish National Health Profile and finding meaning in life (SOME).

Objective measures will be collected at 6 weeks, 6 months, 12 months and 24 months and include: Anorectal manometry that measures anorectal muscle function and rectal perception, a digital examination of anorectal muscle function using the Digital Rectal Examination Scoring System (DRESS) and the six-minute walk test a measure of submaximal exercise capacity.

We plan to analyze the EDFI-Cohort study as repeated measures with both simple and multiple linear regression models for the continuous data. We plan to adjust for known confounders and variables related to treatment.

02

Conditions studied

  • Rectum Cancer
  • Quality of Life
  • Faecal Incontinence
  • Low Anterior Resection Syndrome

Keywords

  • Rectum cancer
  • Low Anterior Rectal Syndrome
  • Anorectal muscle function
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Subjects for the EDFI-Cohort study will be recruited during 2019 and 2020 from Department of Surgery, Slagelse, and Zealand University Hospital, Køge. Subjects need to be diagnosed with rectal cancer and have received curative surgery (low anterior resection) with/without adjuvant (radiation/chemo) therapy.

Inclusion criteria

  • Diagnosis of rectal cancer
  • Low anterior resection (e.g. not limited to total mesorectal excision (TME) or partial mesorectal excision (PME))
  • Ability to communicate in Danish
  • Adults (> 18 years of age)
  • American Society of Anaesthesiologists (ASA) score: I-IV.

Exclusion criteria

Exclusion Criteria:

  • ASA score of: V-VI.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
0 participants (actual)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • EDFI Cohort

    Subjects should have received surgery for rectal cancer (low anterior resection).

    Procedure: Low Anterior Resection for Rectum Cancer

Interventions

  • ProcedureLow Anterior Resection for Rectum Cancer

    Subjects should have received curative surgery for rectal cancer (low anterior resection) with/with-out adjuvant (radiation/chemo) therapy.

    Also known as: Total mesorectal excision, Partial mesorectal excision

05

What researchers measure

Primary outcomes

  1. Global health status/quality of life: EORTC QLQ-C30

    European Organisation for Research and Treatment of Cancer's generic core set on quality of life (EORTC QLQ-C30)

    Time frame: 104 weeks

Secondary outcomes

  1. Low anterior resection syndrome

    Self-reported questionnaire - Low anterior resection symptom - score (LARS-score)

    Time frame: 104 weeks

Other outcomes

  1. Urinary incontinence

    International Consultation on Incontinence Questionnaire - Urinary Incontinence Short Form (ICIQ-UI SF)

    Time frame: 3, 6, 12, 26, 52 and 104 weeks

  2. Urinary incontinence - Urinary symptoms

    International Consultation on Incontinence Questionnaire - Male/female Lower Urinary Tract Symptoms (ICIQ-MLUTS og ICIQ-FLUTS)

    Time frame: 3, 6, 12, 26, 52 and 104 weeks

  3. Urinary incontinence - Sexual dysfunction

    International Consultation on Incontinence Questionnaire - Male/female Sexual Matters associated with Lower Urinary Tract Symptoms (ICIQ-MLUTSsex or ICIQ-FLUTSsex)

    Time frame: 3, 6, 12, 26, 52 and 104 weeks

  4. Global health status/quality of life: EORTC QLQ-C30

    European Organisation for Research and Treatment of Cancer's generic core set on quality of life (EORTC QLQ-C30)

    Time frame: 3, 6, 12, 26 and 52 weeks

  5. Other subscales than 'global health status/quality of life': EORTC QLQ-C30

    European Organisation for Research and Treatment of Cancer's generic core set on quality of life (EORTC QLQ-C30)

    Time frame: 3, 6, 12, 26, 52 and 104 weeks

  6. Quality of life - colorectal cancer: EORTC QLQ-CR29

    European Organisation for Research and Treatment of Cancer's colorectal cancer module (EORTC QLQ-CR29)

    Time frame: 3, 6, 12, 26, 52 and 104 weeks

  7. Quality of life - Fatigue: EORTC QLQ-FA12

    European Organisation for Research and Treatment of Cancer's fatigue module (EORTC QLQ-FA12)

    Time frame: 3, 6, 12, 26, 52 and 104 weeks

  8. Quality of life - INFO: EORTC QLQ-INFO25

    European Organisation for Research and Treatment of Cancer's information about disease and treatment module (EORTC QLQ-INFO25)

    Time frame: 3, 6, 12, 26, 52 and 104 weeks

  9. Anorectal muscle function - digital examination

    Maximal resting pressure Maximal squeeze pressure Endurance squeeze - max squeeze pressure or longest time Latency (rate of force development), number of rectal muscle contractions/squeezes in 15 sec test.

    Time frame: 6, 26, 52 and 104 weeks

  10. Anorectal Manometry - pressure

    Maximal resting pressure Maximal squeeze pressure Maximal squeeze pressure duration

    Time frame: 6, 26, 52 and 104 weeks

  11. Anorectal Manometry - capacity

    Volume capacity measurements: Maximal tolerated volume Conscious rectal sensitivity threshold Conscious rectal sensitivity Constant sensation

    Time frame: 6, 26, 52 and 104 weeks

  12. Faecal incontinence

    Self-reported questionnaire - St. Marks Incontinence score (Vaizey score)

    Time frame: 3, 6, 12, 26, 52 and 104 weeks

  13. Low anterior resection syndrome

    Self-reported questionnaire - Low anterior resection symptom - score (LARS-score)

    Time frame: 3, 6, 12, 26 and 52 weeks

  14. Physical activity level

    physical activity section of the Danish National Health Profile

    Time frame: 3, 6, 12, 26, 52 and 104 weeks

  15. Finding meaning in life

    Sources of Meaning and Meaning in Life Questionnaire (SoMe)

    Time frame: 3, 6, 12, 26, 52 and 104 weeks

  16. Physical performance

    6-Minute Walk test

    Time frame: 6, 26, 52 and 104 weeks

06

Study locations

2 sites
  • Zealand University Hospital
    Køge, Region Zealand DK-4600, Denmark
  • Slagelse Hospital
    Slagelse, Region Zealand DK-4200, Denmark
07

References and documents

Publications

  • Emmertsen KJ, Laurberg S; Rectal Cancer Function Study Group. Impact of bowel dysfunction on quality of life after sphincter-preserving resection for rectal cancer. Br J Surg. 2013 Sep;100(10):1377-87. doi: 10.1002/bjs.9223. PubMed 23939851 ↗
  • Lai X, Wong FK, Ching SS. Review of bowel dysfunction of rectal cancer patients during the first five years after sphincter-preserving surgery: a population in need of nursing attention. Eur J Oncol Nurs. 2013 Oct;17(5):681-92. doi: 10.1016/j.ejon.2013.06.001. Epub 2013 Jul 17. PubMed 23871359 ↗
  • Ma B, Gao P, Song Y, Zhang C, Zhang C, Wang L, Liu H, Wang Z. Transanal total mesorectal excision (taTME) for rectal cancer: a systematic review and meta-analysis of oncological and perioperative outcomes compared with laparoscopic total mesorectal excision. BMC Cancer. 2016 Jul 4;16:380. doi: 10.1186/s12885-016-2428-5. PubMed 27377924 ↗

Study documents

  • Study protocol · Jul 4, 2019
  • Informed consent form · Jul 4, 2019

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided — Reseachers whom are interested in study data, are welcome to contact study PI.

08

Registry details

Key details

Study ID
NCT03257332
Lead sponsor
Slagelse Hospital
Collaborators
Zealand University Hospital, Association of Danish Physiotherapists
Responsible party
Brian Clausen (Physiotherapist and PhD, Slagelse Hospital) — Principal investigator
First posted
Aug 22, 2017
Start date
Nov 12, 2019
Primary completion
Dec 31, 2020 (estimated)
Completion
Dec 31, 2022 (estimated)
Last update
Dec 4, 2020

Study contacts

Søren T Skou, PhD
study chair · Slagelse Sygehus
Ismail Gögenur, PhD
study chair · Zealand University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion